Latest news

• Gilead bags EU approval for next-generation HIV drug

  Descovy was approved by the US FDA earlier this month, while a three-drug combination called Odefsey (emtricitabine, rilpivirine and TAF) - a follow-up to its $1.4bn Complera product - was

• Gilead boosts liver disease pipeline with $1.2bn acquisition

  Descovy is the third TAF-based HIV drug in Gilead's portfolio - joining its other once-daily treatments Genvoya and Odefsey - and adds to the biopharmaceutical firm's dominance in the

• Gilead wins US approval for second TAF-based HIV drug

  FDA gives Odefsey the green light.  . Gilead Sciences has added another new product to its HIV franchise following FDA approval of Odefsey, a three-drug regimen taken as a single small